Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

elzovantinib (TPX-0022)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS, ZAI Lab

Drug class:

Src kinase inhibitor, c-MET inhibitor, CSF-1R inhibitor

Related drugs:

‹

axatilimab-csfr (0)

dasatinib (215)

JNJ-26483327 (0)

tirbanibulin ointment (0)

KX2-391 oral (0)

savolitinib (29)

amivantamab-vmjw (25)

capmatinib (23)

unecritinib (6)

gumarontinib (5)

JNJ-38877605 (1)

EMD 1204831 (0)

PF-04217903 (0)

avapritinib (13)

pexidartinib (6)

axatilimab-csfr (0)

›

MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
MET mutation	Gastric Cancer	MET mutation	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
MET exon 14 deletion	Non Small Cell Lung Cancer	MET exon 14 deletion	Non Small Cell Lung Cancer	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3
MET amplification	Colorectal Cancer	MET amplification	Colorectal Cancer	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3
MET H1094Y	Non Small Cell Lung Cancer	MET H1094Y	Non Small Cell Lung Cancer	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4
MET F1200I	Non Small Cell Lung Cancer	MET F1200I	Non Small Cell Lung Cancer	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4
MET F1200I	Lung Adenocarcinoma	MET F1200I	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4
MET H1094Y	Lung Adenocarcinoma	MET H1094Y	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4